RSV candidate ready for phase I in success for Boston Children's Hospital and Danish researchers

The Danish State Serum Institute (SSI) has helped develop a candidate which has proved effective against the respiratory syncytial virus in mice – next up is human testing.

Photo: Marijan Murat/AP/Ritzau Scanpix

A RSV vaccine candidate for newborns, which was developed in a collaboration between Boston Children’s Hospital and researchers from the Danish State Serum Institute, SSI, has reported promising results after testing with mice, the Danish vaccine authority writes in a press release.

Following the successful study, preparations for human testing have begun.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs